

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
396138	29/09/2016	Female	10	██████ (cannabidiol) - Concomitant (2 days); Trade Name Not Specified (Clobazam) - Suspect (1 days)	Dyspnoea ; Poor feeding infant ; Somnolence
396393	5/10/2016	Female	5	██████ (cannabidiol) - Concomitant (13 days); Trade Name Not Specified (Phenytoin sodium) - Suspect (3 days)	Dysarthria ; Tremor
396436	6/10/2016	Female	10	██████ (cannabidiol) - Suspect (14 days); Trade Name Not Specified (Clobazam) - Suspect (-)	Dyspnoea ; Poor feeding infant ; Somnolence
396967	14/10/2016	Female	2	██████ (cannabidiol) - Suspect (59 days)	Epilepsy ; Irritability
396968	14/10/2016	Male	10	██████ (cannabidiol) - Suspect (27 days); Trade Name Not Specified (Clobazam) - Concomitant (-)	Blood triglycerides increased
396971	14/10/2016	Male	10	██████ (cannabidiol) - Suspect (-)	Epilepsy
398745	10/11/2016	Female	3	██████ (cannabidiol) - Suspect (103 days); Phenobarbital (phenobarbital (phenobarbitone)) - Concomitant (-); Trade Name Not Specified (Levetiracetam) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-); Trade Name Not Specified (stiripentol) - Concomitant (-)	Disease progression ; Seizure
398748	10/11/2016	Male	4	██████ (cannabidiol) - Suspect (77 days); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Sodium valproate) - Concomitant (-); Trade Name Not Specified (rufinamide) - Concomitant (-)	Liver function test increased
398757	10/11/2016	Male	6	██████ (cannabidiol) - Suspect (85 days); Keppra (Levetiracetam) - Concomitant (-); Trade Name Not Specified (Lamotrigine) - Concomitant (-); Trade Name Not Specified (Midazolam) - Concomitant (-); Trade Name Not Specified (Paracetamol) - Concomitant (-); Trade Name Not Specified (Phenytoin sodium) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-); Trade Name Not Specified (iron) - Concomitant (-)	Drug ineffective
398827	11/11/2016	Female	5	██████ (cannabidiol) - Suspect (82 days)	Ataxia ; Irritability
398931	15/11/2016	Male	1	██████ (cannabidiol) - Suspect (-); Trade Name Not Specified (Levetiracetam) - Concomitant (-); Trade Name Not Specified (Nitrazepam) - Concomitant (-); Trade Name Not Specified (Vigabatrin) - Concomitant (-)	Pneumonia
405028	9/03/2017	Female	11	██████ (cannabidiol) - Suspect (13 days); Trade Name Not Specified (Clobazam) - Suspect (-); Trade Name Not	Somnolence

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				Specified (Lacosamide) - Suspect (-); Trade Name Not Specified (Sodium valproate) - Suspect (-); Trade Name Not Specified (rufinamide) - Suspect (-)	
408617	8/05/2017	Female	50	Di-gesic (Dextropropoxyphene hydrochloride ; Paracetamol) - Concomitant (-); ██████████ (cannabidiol ; dronabinol) - Suspect (0 days); Trade Name Not Specified (Clonazepam) - Concomitant (-); Trade Name Not Specified (Fentanyl) - Concomitant (-); Trade Name Not Specified (Lamotrigine) - Concomitant (-); Trade Name Not Specified (Phenytoin sodium) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-); Trade Name Not Specified (Zonisamide) - Concomitant (-)	Delusion ; Drug ineffective ; Hallucination ; Somnolence
409506	18/05/2017	Male	9	██████████ (cannabidiol) - Suspect (161 days); Epilim (Sodium valproate) - Suspect (1641 days); Zonegran (Zonisamide) - Concomitant (-)	Drug interaction ; Toxicity to various agents
410143	22/05/2017	Male	5	██████████ (cannabidiol) - Suspect (158 days); Epilim (Sodium valproate) - Suspect (644 days); Keppra (Levetiracetam) - Concomitant (47 days); Trade Name Not Specified (Lamotrigine) - Concomitant (54 days); Trade Name Not Specified (Melatonin) - Concomitant (1638 days)	Toxicity to various agents
410235	17/05/2017	Female	50	██████████ (cannabidiol ; dronabinol) - Suspect (-); Trade Name Not Specified (Clonazepam) - Concomitant (-); Trade Name Not Specified (Fentanyl) - Concomitant (-); Trade Name Not Specified (Lamotrigine) - Concomitant (-); Trade Name Not Specified (Phenytoin sodium) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-); Trade Name Not Specified (Zonisamide) - Concomitant (-)	Delusion ; Drug ineffective ; Hallucination
410510	25/05/2017	Female	9	██████████ (cannabidiol) - Suspect (43 days); Trade Name Not Specified (Oxcarbazepine) - Concomitant (-); Trade Name Not Specified (Sirolimus) - Concomitant (-); Trade Name Not Specified (Vigabatrin) - Concomitant (-); Trade Name Not Specified (rufinamide) - Concomitant (-)	Drug level increased

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
412763	26/06/2017	Female	7	██████████ (cannabidiol) - Suspect (56 days)	Decreased appetite ; Somnolence ; Vomiting ; Weight decreased
412793	26/06/2017	Female	16	Dilantin (Phenytoin sodium) - Concomitant (-); ██████████ (cannabidiol) - Suspect (13 days); Keppra (Levetiracetam) - Concomitant (-); Levlen ED (ethinylestradiol ; Levonorgestrel) - Suspect (889 days); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Gabapentin) - Concomitant (-); Trade Name Not Specified (Omeprazole) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-)	Metrorrhagia ; Metrorrhagia
413988	12/07/2017	Female	50	██████████ (cannabidiol ; dronabinol) - Suspect (31 days)	Somnolence
415680	8/08/2017	Female	16	██████████ (cannabidiol) - Suspect (59 days)	International normalised ratio increased
415682	8/08/2017	Female	16	██████████ (cannabidiol) - Suspect (14 days)	Vaginal haemorrhage
415683	8/08/2017	Male	8	██████████ (cannabidiol) - Suspect (35 days)	Liver function test increased
418633	21/09/2017	Female	4	██████████ (cannabidiol) - Suspect (159 days); Trade Name Not Specified (Baclofen) - Concomitant (-); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Gabapentin) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-); Trade Name Not Specified (amitriptyline hydrochloride) - Concomitant (-); Trade Name Not Specified (esomeprazole) - Concomitant (-)	Diarrhoea
419670	11/10/2017	Female	12	██████████ (cannabidiol) - Suspect (69 days)	Somnolence
419672	11/10/2017	Female	17	██████████ (cannabidiol) - Suspect (29 days); Phenobarbital (phenobarbital (phenobarbitone)) - Concomitant (-); Trade Name Not Specified (Clonidine hydrochloride) - Concomitant (-)	Abnormal behaviour ; Aggression
419673	11/10/2017	Male	-	██████████ (cannabidiol) - Suspect (20 days); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-); Trade Name Not Specified (rufinamide) - Concomitant (-)	Somnolence
419676	11/10/2017	Male	4	██████████ (cannabidiol) - Suspect (75 days); Epilim (Sodium valproate) - Concomitant (-); Trade Name Not Specified (ketamine) - Concomitant (-)	Liver function test ; Malaise ; Pneumonitis

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
419678	11/10/2017	Female	5	██████████ (cannabidiol) - Suspect (35 days); Epilim (Sodium valproate) - Concomitant (-); Phenobarbital (phenobarbital (phenobarbitone)) - Concomitant (-); Trade Name Not Specified (Clobazam) - Concomitant (-)	Somnolence
420517	24/10/2017	Female	14	██████████ (cannabidiol) - Suspect (18 days); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Lacosamide) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-)	Somnolence
421067	1/11/2017	Male	12	██████████ (cannabidiol) - Suspect (46 days)	Clumsiness ; Seizure
421075	1/11/2017	Male	12	Catapres (Clonidine hydrochloride) - Concomitant (-); ██████████ (cannabidiol) - Suspect (27 days); Epilim (Sodium valproate) - Suspect (46 days); Frisium (Clobazam) - Concomitant (-); Lamictal (Lamotrigine) - Concomitant (-); Ospolot (sulthiame) - Concomitant (-)	Liver function test increased
421915	14/11/2017	Male	13	██████████ (cannabidiol) - Suspect (31 days); Trade Name Not Specified (Clobazam) - Concomitant (-)	Somnolence
421917	14/11/2017	Female	14	██████████ (cannabidiol) - Suspect (28 days); Trade Name Not Specified (Clobazam) - Concomitant (-)	Somnolence
425258	9/01/2018	Male	9	██████████ (cannabidiol) - Suspect (-); Epilim (Sodium valproate) - Concomitant (-); Trade Name Not Specified (Clobazam) - Concomitant (-)	Liver function test increased
425408	12/01/2018	Male	17	██████████ (cannabidiol) - Suspect (2174 days)	Vomiting
425411	12/01/2018	Female	6	██████████ (cannabidiol) - Interacting (-); Trade Name Not Specified (Clobazam) - Interacting (-)	Somnolence
425413	12/01/2018	Male	4	██████████ (cannabidiol) - Interacting (-); Epilim (Sodium valproate) - Interacting (-)	Liver function test increased
426478	1/02/2018	Female	5	██████████ (cannabidiol) - Suspect (363 days); Epilim (Sodium valproate) - Concomitant (-); Phenobarbital (phenobarbital (phenobarbitone)) - Concomitant (-); Trade Name Not Specified (Clobazam) - Concomitant (-)	Liver function test increased
427474	15/02/2018	Unknown	-	██████████ (cannabidiol) - Suspect (115 days); Trade Name Not Specified (Clobazam) - Concomitant (-)	Somnolence
427983	22/02/2018	Male	13	██████████ (cannabidiol ; dronabinol) - Suspect (16 days); Trade Name Not Specified (Clobazam) - Suspect (-); Trade Name Not	Sedation

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				Specified (Sodium valproate) - Concomitant (-); Trade Name Not Specified (rufinamide) - Concomitant (-)	
429104	13/03/2018	Female	12	██████████ (cannabidiol) - Suspect (218 days); Phenobarbital (phenobarbital (phenobarbitone)) - Concomitant (-); Trade Name Not Specified (Clobazam) - Concomitant (-)	Alopecia
429105	13/03/2018	Female	13	██████████ (cannabidiol) - Suspect (3821 days); Epilim (Sodium valproate) - Concomitant (-); Trade Name Not Specified (Clobazam) - Concomitant (-)	Alopecia
430040	26/03/2018	Female	6	██████████ (cannabidiol) - Suspect (-); Epilim (Sodium valproate) - Concomitant (-)	Liver function test increased ; Pneumonia
431216	13/04/2018	Female	11	██████████ (cannabidiol) - Suspect (240 days); Epilim (Sodium valproate) - Concomitant (-); Keppra (Levetiracetam) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-)	Drug ineffective ; Fatigue ; Somnolence
431480	18/04/2018	Female	18	██████████ (cannabidiol) - Interacting (46 days); Trade Name Not Specified (Clobazam) - Interacting (-)	Somnolence
432186	30/04/2018	Female	8	██████████ (cannabidiol) - Suspect (-); Epilim (Sodium valproate) - Suspect (-)	Liver function test increased
433280	14/05/2018	Female	14	██████████ (cannabidiol) - Suspect (67 days); Trade Name Not Specified (Clobazam) - Concomitant (-)	Somnolence
434647	30/05/2018	Female	8	██████████ (cannabidiol) - Suspect (29 days); Trade Name Not Specified (Clobazam) - Suspect (-); Trade Name Not Specified (Clonazepam) - Concomitant (-)	Somnolence
436266	18/06/2018	Male	17	██████████ (cannabidiol) - Suspect (3654 days); Epilim (Sodium valproate) - Concomitant (-); Keppra (Levetiracetam) - Concomitant (-); Lamictal (Lamotrigine) - Concomitant (-)	Diarrhoea
436362	18/06/2018	Female	-	APO-Sodium valproate (Sodium valproate) - Concomitant (-); ██████████ (cannabidiol) - Suspect (-); Frisium (Clobazam) - Concomitant (-)	Asthenia ; Dyspnoea ; Epistaxis ; Faeces discoloured ; Fatigue ; Nausea ; Pain ; Peripheral swelling ; Seizure cluster
436471	18/06/2018	Female	-	██████████ (cannabidiol) - Suspect (-)	Asthenia ; Dyspnoea ; Epistaxis ; Faeces discoloured ; Fatigue ; Insomnia ; Melaena ; Nausea ; Peripheral swelling ; Seizure ; Somnolence ; Tremor

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
437326	4/07/2018	Male	30	██████████ (cannabidiol ; dronabinol) - Suspect (-)	Dry mouth ; Somnolence
439209	30/07/2018	Male	13	██████████ (cannabidiol) - Suspect (156 days)	Diarrhoea
440307	13/08/2018	Female	29	Trade Name Not Specified (cannabidiol) - Suspect (-)	Electrolyte imbalance ; Hypophagia ; Nausea ; Vomiting
442375	31/08/2018	Female	13	██████████ (cannabidiol) - Concomitant (-); Morphine (morphine sulfate pentahydrate) - Concomitant (-); ██████████ (cannabidiol) - Suspect (-); Trade Name Not Specified (Amlodipine) - Concomitant (-); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Clonazepam) - Concomitant (-); Trade Name Not Specified (Gabapentin) - Concomitant (-); Trade Name Not Specified (Lamotrigine) - Concomitant (-); Trade Name Not Specified (Melatonin) - Concomitant (-); Trade Name Not Specified (Midazolam) - Concomitant (-); Valproate Winthrop (Sodium valproate) - Concomitant (-)	Disease progression
442389	31/08/2018	Female	<1	██████████ (cannabidiol) - Suspect (-); Trade Name Not Specified (Carnitine) - Concomitant (-); Trade Name Not Specified (Clobazam) - Suspect (-); Trade Name Not Specified (Clonazepam) - Concomitant (-); Trade Name Not Specified (Ethosuximide) - Concomitant (-); Trade Name Not Specified (Melatonin) - Concomitant (-); Trade Name Not Specified (Sodium valproate) - Concomitant (-)	Somnolence
442391	31/08/2018	Female	15	██████████ (cannabidiol) - Suspect (-); Norimin-1 28 (ethinylloestradiol ; Norethisterone) - Concomitant (-); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Ethosuximide) - Concomitant (-); Trade Name Not Specified (Fluoxetine hydrochloride) - Concomitant (-); Trade Name Not Specified (Sodium valproate) - Concomitant (-); Trade Name Not Specified (Zonisamide) - Concomitant (-)	Abdominal pain upper ; Decreased appetite ; Diarrhoea ; Nausea
443512	7/09/2018	Male	41	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (0 days)	Headache ; Nausea
443804	12/09/2018	Female	81	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Rash

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				valproate) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Interacting (-); Trade Name Not Specified (mometasone furoate) - Concomitant (-)	
447425	15/10/2018	Male	8	Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Risperidone) - Concomitant (-); Trade Name Not Specified (Sertraline hydrochloride) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Suspect (-)	Abdominal pain ; Behaviour disorder ; Decreased appetite ; Diarrhoea
447466	15/10/2018	Male	7	Trade Name Not Specified (Clobazam) - Interacting (-); Trade Name Not Specified (Lacosamide) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Interacting (-); Trade Name Not Specified (rufinamide) - Concomitant (-)	Sedation
447481	15/10/2018	Male	16	Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (brivaracetam) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Suspect (-)	Anal incontinence ; Diarrhoea
448334	20/10/2018	Female	26	██████████ (cannabidiol ; dronabinol) - Interacting (-); Trade Name Not Specified (Clarithromycin) - Interacting (-); Trade Name Not Specified (Rifampicin) - Interacting (-)	Altered state of consciousness ; Dizziness ; Increased appetite ; Somnolence
450631	15/11/2018	Male	12	Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Lacosamide) - Concomitant (-); Trade Name Not Specified (Lamotrigine) - Concomitant (-); Trade Name Not Specified (Melatonin) - Concomitant (-); Trade Name Not Specified (Sodium valproate) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Suspect (-)	Pneumonia
450634	15/11/2018	Male	6	Trade Name Not Specified (Sodium valproate) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-); Trade Name Not Specified (calcium) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Suspect (-)	Liver function test abnormal
451230	22/11/2018	Female	6	Disodium Pamidronate (pamidronate disodium) - Concomitant (-); Epilim (Sodium valproate) - Suspect (-); Fish Oil (natural fish oil) - Concomitant (-); Salbutamol (Salbutamol) - Concomitant (-); Trade Name Not Specified (Azithromycin) - Concomitant (-); Trade Name Not Specified (Biotin) - Concomitant (-); Trade Name Not Specified (Clobazam) - Suspect (-); Trade Name Not Specified	Gamma-glutamyltransferase increased ; Lower respiratory tract infection ; Pneumonia ; Somnolence

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				(Lansoprazole) - Concomitant (-); Trade Name Not Specified (Levetiracetam) - Concomitant (-); Trade Name Not Specified (Omeprazole) - Concomitant (-); Trade Name Not Specified (Zonisamide) - Concomitant (-); Trade Name Not Specified (calcium) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Suspect (-); Trade Name Not Specified (colecalfiferol) - Concomitant (-); Trade Name Not Specified (sodium chloride) - Concomitant (-)	
452048	30/11/2018	Female	-	██████████ (cannabidiol) - Suspect (-)	Drug ineffective
454809	14/01/2019	Female	21	Trade Name Not Specified (cannabidiol) - Suspect (-)	Unresponsive to stimuli
454909	15/01/2019	Male	-	Trade Name Not Specified (cannabidiol) - Suspect (-)	Diarrhoea ; Hallucination ; Vomiting
455139	17/01/2019	Male	35	██████████ (cannabidiol) - Suspect (-); Loperamide (Loperamide hydrochloride) - Concomitant (-); Panadol Osteo (Paracetamol) - Concomitant (-); Paxam (Clonazepam) - Concomitant (-); Trade Name Not Specified (Bromhexine hydrochloride) - Concomitant (-); Trade Name Not Specified (Carbamazepine) - Concomitant (-); Trade Name Not Specified (Ciprofloxacin) - Concomitant (-); Trade Name Not Specified (Lacosamide) - Concomitant (-); Trade Name Not Specified (Midazolam) - Concomitant (-); Trade Name Not Specified (Sodium valproate) - Concomitant (-); Trade Name Not Specified (perampanel) - Concomitant (-)	Epilepsy ; Product quality issue ; Quality of life decreased ; Seizure ; Urinary tract infection
456094	31/01/2019	Male	5	██████████ (cannabidiol) - Suspect (-); Epilim (Sodium valproate) - Concomitant (-); Trade Name Not Specified (Diazepam) - Concomitant (-); Vimpat (Lacosamide) - Concomitant (-)	Liver function test abnormal ; Vomiting
456210	1/02/2019	Female	89	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Drug ineffective ; Fatigue
456431	5/02/2019	Male	5	██████████ (cannabidiol) - Suspect (-); Epilim (Sodium valproate) - Concomitant (-); Trade Name Not Specified (Clonazepam) - Concomitant (-); Vimpat (Lacosamide) - Concomitant (-)	Liver function test abnormal ; Vomiting
456795	11/02/2019	Female	55	Trade Name Not Specified (Lacosamide) - Concomitant (-); Trade Name Not Specified (Levetiracetam) - Concomitant (-); Trade Name Not Specified (Zonisamide) - Concomitant (-); Trade Name Not Specified (atorvastatin) - Concomitant (-); ██████████	Sudden unexplained death in epilepsy

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				██████████ (Cannabidiol ██████████ ██████████ - Suspect (-)	
457407	18/02/2019	Male	19	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Clonazepam) - Concomitant (-); Trade Name Not Specified (Midazolam) - Concomitant (-); Trade Name Not Specified (Product not Coded) - Concomitant (-); Trade Name Not Specified (Sodium valproate) - Concomitant (-); Trade Name Not Specified (brivaracetam) - Concomitant (-); Trade Name Not Specified (perampanel) - Concomitant (-)	Myoclonic epilepsy ; Spinal muscular atrophy
457992	22/02/2019	Female	62	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Dizziness
458328	27/02/2019	Female	52	Dilaudid (hydromorphone hydrochloride) - Suspect (-); Opsumit (Macitentan) - Suspect (887 days); Phenergan (Promethazine hydrochloride) - Concomitant (-); Promethazine (Promethazine hydrochloride) - Concomitant (-); Serepax (Oxazepam) - Concomitant (-); Trade Name Not Specified (Apixaban) - Concomitant (-); Trade Name Not Specified (CANNABIS SATIVA) - Concomitant (-); Trade Name Not Specified (Hydromorphone) - Concomitant (-); Trade Name Not Specified (Oxazepam) - Concomitant (-); Trade Name Not Specified (Oxygen) - Concomitant (-); Trade Name Not Specified (Sildenafil) - Suspect (887 days); Trade Name Not Specified (Sildenafil) - Suspect (897 days); Trade Name Not Specified (Spironolactone) - Concomitant (902 days); Trade Name Not Specified (Tadalafil) - Suspect (-); Trade Name Not Specified (furosemide (frusemide)) - Concomitant (675 days); Ventavis (Iloprost) - Suspect (495 days)	Bedridden ; Cardiac failure ; Deep vein thrombosis ; Device related infection ; Dysphagia ; Dyspnoea ; Erythema ; Foot fracture ; Gait disturbance ; Malaise ; Pain ; Peripheral swelling ; Treatment noncompliance ; Vascular device infection
458427	27/02/2019	Female	71	Targin (naloxone hydrochloride dihydrate ; oxycodone hydrochloride) - Suspect (-); Trade Name Not Specified (Pregabalin) - Suspect (-); Trade Name Not Specified (Tapentadol) - Suspect (-); Trade Name Not Specified (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Drug withdrawal convulsions
459423	13/03/2019	Male	35	██████████ (cannabidiol ; dronabinol) - Suspect (-)	Dysphoria ; Urticaria

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
460678	26/03/2019	Female	5	Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Loratadine) - Concomitant (-); Trade Name Not Specified (Melatonin) - Concomitant (-); Trade Name Not Specified (Product not Coded) - Concomitant (-); Trade Name Not Specified (Sodium valproate) - Concomitant (-); ██████████ (Cannabidiol ██████████) - Suspect (-)	Status epilepticus
460689	26/03/2019	Female	78	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Balance disorder ; Hallucination ; Memory impairment
461451	3/04/2019	Male	35	██████████ (cannabidiol) - Suspect (-)	Dysphoria ; Rash
461483	3/04/2019	Female	18	██████████ (cannabidiol) - Suspect (-); Epilim (Sodium valproate) - Concomitant (-); Keppra (Levetiracetam) - Concomitant (-)	Liver function test increased
461521	3/04/2019	Female	66	██████████ (cannabidiol) - Suspect (-)	Urticaria
462218	10/04/2019	Female	61	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Nausea
462395	11/04/2019	Female	75	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Seizure
462397	11/04/2019	Female	33	██████████ (cannabidiol) - Suspect (-)	Drug ineffective ; Therapeutic response decreased
462406	11/04/2019	Female	72	██████████ (cannabidiol) - Suspect (-)	Drug ineffective
462408	11/04/2019	Unspecified	61	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Therapeutic response decreased
462412	11/04/2019	Female	83	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Drug ineffective
464318	6/05/2019	Female	55	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (0 days)	Concomitant disease aggravated ; Condition aggravated ; Fatigue ; Psychomotor hyperactivity
465486	16/05/2019	Female	48	██████████ (cannabidiol) - Suspect (-)	Abdominal distension ; Flatulence
466055	22/05/2019	Female	54	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Anxiety ; Cognitive disorder

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
466805	29/05/2019	Female	54	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-); Madopar (Benserazide hydrochloride ; Levodopa) - Concomitant (-); Trade Name Not Specified (Amantadine hydrochloride) - Concomitant (-)	Condition aggravated ; Dyspnoea
467161	3/06/2019	Female	42	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Decreased appetite ; Depression ; Disorientation ; Dizziness ; Dry mouth ; Fatigue ; Nausea ; Tinnitus
467328	4/06/2019	Female	73	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (3 days)	Rash ; Swelling
467370	4/06/2019	Female	-	██████████ (cannabidiol) - Suspect (-)	Hepatic enzyme increased
467460	5/06/2019	Unspecified	43	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Abdominal pain ; Drug ineffective
467625	7/06/2019	Female	7	Bactrim (Sulfamethoxazole ; Trimethoprim) - Concomitant (-); ██████████ (cannabidiol) - Suspect (-); Trade Name Not Specified (Clobazam) - Suspect (-)	Pneumonia aspiration ; Somnolence ; Thrombocytopenia ; Urinary tract infection
467629	7/06/2019	Female	77	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (3 days)	Dizziness
468303	14/06/2019	Female	39	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Drug ineffective ; Fatigue ; Nausea
468959	21/06/2019	Female	14	██████████ (cannabidiol) - Suspect (-)	Tooth discolouration
470430	5/07/2019	Male	4	██████████ (cannabidiol) - Suspect (-)	Epileptic encephalopathy
471180	15/07/2019	Female	90	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Secretion discharge
472252	28/07/2019	Male	66	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Nausea
472253	28/07/2019	Male	74	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Balance disorder ; Confusional state
472568	31/07/2019	Male	19	Trade Name Not Specified (Melatonin) - Concomitant (-); Trade Name Not Specified (Risperidone) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Suspect (-)	Sleep apnoea syndrome
472570	31/07/2019	Female	11	██████████ (cannabidiol) - Suspect (-); Ozmep omeprazole 20 mg enteric-coated tablet blister (Omeprazole) - Concomitant (-); Trade Name Not Specified (Baclofen) - Concomitant (-); Trade	Feeding disorder ; Irritability

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				Name Not Specified (Clonidine) - Concomitant (-); Trade Name Not Specified (Diazepam) - Concomitant (-); Trade Name Not Specified (Gabapentin) - Concomitant (-)	
473052	6/08/2019	Male	59	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Dizziness ; Fatigue ; Nausea
473069	7/08/2019	Male	85	Atrovent (ipratropium bromide) - Concomitant (-); Glyade (Gliclazide) - Concomitant (-); Imdur (Isosorbide mononitrate) - Concomitant (-); Lasix (furosemide (frusemide)) - Concomitant (-); Lipitor (Atorvastatin calcium) - Concomitant (-); Lyrica (Pregabalin) - Concomitant (-); Nebilet (Nebivolol) - Concomitant (-); Pariet (Rabeprazole sodium) - Concomitant (-); Physiotens (Moxonidine) - Concomitant (-); Plavix (Clopidogrel) - Concomitant (-); Prazosin (Prazosin hydrochloride) - Concomitant (-); SINGULAIR (Montelukast) - Concomitant (-); Salazopyrin (Sulfasalazine) - Concomitant (-); Salbutamol (Salbutamol) - Concomitant (-); Spiractin (Spironolactone) - Concomitant (-); Symbicort (Budesonide ; formoterol (eformoterol) fumarate dihydrate) - Concomitant (-); Targin (naloxone hydrochloride dihydrate ; oxycodone hydrochloride) - Concomitant (-); Trade Name Not Specified (Budesonide) - Concomitant (-); Trade Name Not Specified (Ergocalciferol) - Concomitant (-); Trade Name Not Specified (Mepolizumab) - Suspect (-); Trade Name Not Specified (Mepolizumab) - Suspect (-254 days); Trade Name Not Specified (Mepolizumab) - Suspect (59 days); Trade Name Not Specified (Mirtazapine) - Concomitant (-); Trade Name Not Specified (Prednisone) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Concomitant (-); Trade Name Not Specified (folic acid) - Concomitant (-); Ventolin (Salbutamol) - Concomitant (-); Zandip (Lercanidipine hydrochloride) - Concomitant (-)	Back pain ; Cough ; Death ; Dyspnoea ; Erythema ; Inappropriate schedule of product administration ; Lower respiratory tract infection ; Malaise ; Oedema peripheral ; Oxygen saturation decreased ; Pain in extremity ; Peripheral swelling ; Respiratory tract infection ; Upper respiratory tract infection
473094	7/08/2019	Male	33	██████████ (cannabidiol) - Suspect (-)	Diarrhoea ; Nausea
473249	8/08/2019	Male	40	Champix (Varenicline) - Concomitant (-); Cymbalta (Duloxetine hydrochloride) - Concomitant (-); Duloxetine (Duloxetine hydrochloride) - Concomitant (-); Lyrica (Pregabalin) - Concomitant (-); Quetiapine XR (Quetiapine) - Concomitant (-);	Adjustment disorder with depressed mood ; Adverse drug reaction ; Anxiety ; Chills ; Constipation ; Dehydration ; Depressed mood ; Fatigue ; Gait disturbance ; Genital rash ;

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				Seroquel (Quetiapine ; Quetiapine fumarate) - Concomitant (539 days); Slow-K (potassium chloride) - Concomitant (479 days); Trade Name Not Specified (Agomelatine) - Concomitant (-); Trade Name Not Specified (Alemtuzumab) - Suspect (478 days); Trade Name Not Specified (Alemtuzumab) - Suspect (479 days); Trade Name Not Specified (Alemtuzumab) - Suspect (878 days); Trade Name Not Specified (Baclofen) - Concomitant (-); Trade Name Not Specified (Baclofen) - Concomitant (1715 days); Trade Name Not Specified (Diazepam) - Concomitant (-); Trade Name Not Specified (Famciclovir) - Concomitant (-); Trade Name Not Specified (Hydrocortisone) - Concomitant (479 days); Trade Name Not Specified (Melatonin) - Concomitant (-); Trade Name Not Specified (Methylprednisolone) - Concomitant (479 days); Trade Name Not Specified (Metoclopramide) - Concomitant (1557 days); Trade Name Not Specified (Pantoprazole) - Concomitant (1165 days); Trade Name Not Specified (Paroxetine) - Concomitant (-); Trade Name Not Specified (Pregabalin) - Concomitant (-); Trade Name Not Specified (Quetiapine) - Concomitant (-); Trade Name Not Specified (Temazepam) - Concomitant (877 days); Trade Name Not Specified (betahistine dihydrochloride) - Concomitant (1557 days); Trade Name Not Specified (cannabidiol) - Concomitant (-); Trade Name Not Specified (colecalfiferol) - Concomitant (1968 days)	Headache ; Headache ; Headache ; Headache ; Herpes zoster ; Herpes zoster ; Inguinal hernia ; Insomnia ; Intentional overdose ; Lower respiratory tract infection ; Muscle spasms ; Muscular weakness ; Nausea ; Nausea ; Nausea ; Nausea ; Personality disorder ; Post herpetic neuralgia ; Rash ; Serotonin syndrome ; Suicidal behaviour ; Suicidal ideation ; Urinary tract infection ; Vomiting
473338	8/08/2019	Female	43	Coloxyl With Senna (Docusate sodium ; Sennosides) - Concomitant (-); Goserelin (goserelin acetate) - Concomitant (-); Morphine (morphine sulfate pentahydrate) - Concomitant (-); ██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-); Thiamine (Thiamine hydrochloride) - Concomitant (-); Trade Name Not Specified (Bisacodyl) - Concomitant (-); Trade Name Not Specified (Exemestane) - Concomitant (-); Trade Name Not Specified (Macrogol) - Concomitant (-); Trade Name Not Specified (Metoclopramide) - Concomitant (-); Trade Name Not Specified (Mirtazapine) - Concomitant (-); Trade Name Not Specified (Ondansetron) - Concomitant (-); Trade Name Not Specified (amoxicillin) - Concomitant (-); Trade Name Not Specified	Diarrhoea ; Nausea ; Vomiting

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				(calcium ; Ergocalciferol) - Concomitant (-); Trade Name Not Specified (doxycycline) - Concomitant (-); Trade Name Not Specified (everolimus) - Suspect (-); Trade Name Not Specified (sodium bicarbonate) - Concomitant (-); Xgeva (Denosumab) - Concomitant (-)	
473551	12/08/2019	Female	28	██████████ (cannabidiol) - Suspect (-)	Diarrhoea
473691	13/08/2019	Male	57	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-); Nexium (esomeprazole) - Concomitant (-)	Chest discomfort ; Chills ; Muscle spasms ; Sedation ; Tachycardia
474065	16/08/2019	Female	43	Coloxyl With Senna (Docusate sodium ; Sennosides) - Concomitant (-); Goserelin (goserelin acetate) - Concomitant (-); Kapanol (morphine sulfate pentahydrate) - Concomitant (-); ██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (19 days); Ordine (morphine hydrochloride trihydrate) - Concomitant (-); Thiamine (Thiamine hydrochloride) - Concomitant (-); Trade Name Not Specified (Cyclizine) - Concomitant (-); Trade Name Not Specified (Dexamethasone) - Drug Not Administered (-); Trade Name Not Specified (Exemestane) - Concomitant (-); Trade Name Not Specified (Haloperidol) - Concomitant (-); Trade Name Not Specified (Mirtazapine) - Concomitant (-); Trade Name Not Specified (Ondansetron) - Concomitant (-); Trade Name Not Specified (Pantoprazole) - Concomitant (-); Trade Name Not Specified (Paracetamol) - Concomitant (-); Trade Name Not Specified (Product not Coded) - Concomitant (-); Trade Name Not Specified (Temazepam) - Concomitant (-); Trade Name Not Specified (colecalfiferol) - Concomitant (-); Trade Name Not Specified (everolimus) - Drug Not Administered (-); Trade Name Not Specified (macrogol 3350 ; potassium chloride ; sodium bicarbonate ; sodium chloride) - Concomitant (-); Trade Name Not Specified (sodium bicarbonate) - Concomitant (-); Xgeva (Denosumab) - Concomitant (-)	Dyspnoea ; Lethargy ; Nausea ; Non-cardiac chest pain
474148	19/08/2019	Male	46	Actiq lozenges (Fentanyl) - Concomitant (-); ClearLax (Macrogol) - Concomitant (-); Dilaudid (hydromorphone hydrochloride) - Concomitant (-); ██████████ (cannabidiol ; Tetrahydrocannabinol	Concomitant disease aggravated ; Lethargy ; Pyrexia

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				(THC) - Suspect (1 days); Thiamine (Thiamine hydrochloride) - Concomitant (-); Trade Name Not Specified (Colchicine) - Concomitant (-); Trade Name Not Specified (Cyclizine) - Concomitant (-); Trade Name Not Specified (Fentanyl) - Concomitant (-); Trade Name Not Specified (Pantoprazole) - Concomitant (-); Trade Name Not Specified (Paracetamol) - Concomitant (-); Trade Name Not Specified (Product not Coded) - Concomitant (-)	
474154	19/08/2019	Female	11	██████████ (cannabidiol) - Suspect (-); Ozemp omeprazole 20 mg enteric-coated tablet blister (Omeprazole) - Concomitant (-); Trade Name Not Specified (Baclofen) - Concomitant (-); Trade Name Not Specified (Clonidine) - Concomitant (-); Trade Name Not Specified (Diazepam) - Concomitant (-); Trade Name Not Specified (Gabapentin) - Concomitant (-)	Feeding disorder ; Irritability
474481	21/08/2019	Male	67	██ (cannabidiol) - Suspect (-)	Fatigue ; Suicide attempt
474835	26/08/2019	Female	45	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Agitation ; Hallucination, visual ; Irritability
475169	28/08/2019	Female	45	██████████ (cannabidiol) - Suspect (-)	Mood altered
475171	28/08/2019	Female	81	██████████ (cannabidiol) - Suspect (-)	Heart rate increased ; Hypotension ; Nausea
475981	6/09/2019	Unspecified	70	Apomine (apomorphine hydrochloride hemihydrate) - Suspect (-); Avanza (Mirtazapine) - Concomitant (-); Imovane (Zopiclone) - Concomitant (-); Kinson (carbidopa monohydrate ; Levodopa) - Concomitant (-); Madopar (Benserazide hydrochloride ; Levodopa) - Concomitant (-); Micardis (Telmisartan) - Concomitant (-); Neupro (Rotigotine) - Concomitant (-); Trade Name Not Specified (Allopurinol) - Concomitant (-); Trade Name Not Specified (Atenolol) - Concomitant (-); Trade Name Not Specified (CANNABIS SATIVA) - Concomitant (-); Trade Name Not Specified (Clonazepam) - Concomitant (-); Trade Name Not Specified (Moclobemide) - Concomitant (-); Trade Name Not Specified (aripiprazole) - Concomitant (-)	Lower respiratory tract infection ; Nausea ; Pneumonia ; Vomiting
476088	9/09/2019	Female	54	██████████ ██████████ (cannabidiol) - Suspect (-)	Diarrhoea ; Lethargy ; Nausea ; Syncope ; Vomiting

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
476238	10/09/2019	Male	89	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Amnesia ; Pain
476247	10/09/2019	Female	57	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Colitis ; Hypophagia ; Liver abscess ; Pain ; Urosepsis
476361	11/09/2019	Female	42	Endone (oxycodone hydrochloride) - Concomitant (-); Lexapro (Escitalopram) - Concomitant (-); ██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (53 days); Palexia (Tapentadol) - Concomitant (-); Targin (naloxone hydrochloride dihydrate ; oxycodone hydrochloride) - Concomitant (-)	Abdominal pain
476602	13/09/2019	Female	30	Promethazine (Promethazine hydrochloride) - Suspect (-); Trade Name Not Specified (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Altered state of consciousness ; Presyncope
476729	16/09/2019	Male	59	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Headache
477082	19/09/2019	Female	97	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (56 days)	Nausea ; Treatment noncompliance ; Vomiting
477134	19/09/2019	Female	44	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Hyperglycaemia
477137	19/09/2019	Female	41	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Suicidal ideation
477228	20/09/2019	Female	57	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Pancreatic carcinoma metastatic
477415	23/09/2019	Female	81	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Hypersensitivity
477631	25/09/2019	Male	25	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Psychotic disorder
477836	27/09/2019	Female	5	Trade Name Not Specified (Sodium valproate) - Suspect (-); Trade Name Not Specified (Topiramate) - Concomitant (-); Trade Name Not Specified (cannabidiol) - Suspect (-)	Hepatitis ; Pancreatitis
478813	11/10/2019	Female	28	Levlen ED (ethinylestradiol ; Levonorgestrel) - Suspect (-); ██████████ (cannabidiol) - Suspect (-); Venlafaxine (Venlafaxine hydrochloride) - Suspect (-)	Drug ineffective
479110	16/10/2019	Female	59	Caltrate (Calcium carbonate) - Concomitant (-); Tegretol (Carbamazepine) - Concomitant (-); Thyroxine (levothyroxine	Headache

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				sodium) - Concomitant (-); ██████████ ██████████ (Cannabidiol 125mg CBD in 2.98g of gel) - Suspect (-)	
479791	23/10/2019	Female	44	Depo-Provera (Medroxyprogesterone acetate) - Concomitant (-); ██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-); Symbicort (Budesonide ; formoterol (eformoterol) fumarate dihydrate) - Concomitant (-)	Gastroenteritis
480205	28/10/2019	Female	82	Cenovis Vitamin C - 53666 (Ascorbic acid ; sodium ascorbate) - Concomitant (-); Hylo-forte (Sodium hyaluronate) - Concomitant (-); ██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-); Nexium (esomeprazole) - Concomitant (-); Ostelin Vitamin D and Calcium (Calcium carbonate ; Cholecalciferol) - Concomitant (-); Ovestin (estriol) - Concomitant (-); Panadol Osteo (Paracetamol) - Concomitant (-); Progynova (estradiol valerate) - Concomitant (-)	Balance disorder ; Decreased appetite ; Diarrhoea ; Dizziness ; Dry eye ; Dry mouth ; Emotional disorder ; Weight decreased
480259	28/10/2019	Female	82	██████████ (cannabidiol) - Suspect (-)	Lip swelling ; Swelling face
480327	29/10/2019	Female	70	Olmesartan (Olmesartan medoxomil) - Concomitant (-); Trade Name Not Specified (CANNABIS SATIVA) - Concomitant (-); Trade Name Not Specified (Hydrocortisone) - Concomitant (361 days); Trade Name Not Specified (Ipilimumab) - Suspect (46 days); Trade Name Not Specified (Metoclopramide) - Concomitant (33 days); Trade Name Not Specified (Paracetamol) - Concomitant (-); Trade Name Not Specified (Product not Coded) - Concomitant (-); Trade Name Not Specified (Triamcinolone acetonide) - Concomitant (293 days); Trade Name Not Specified (Triamcinolone acetonide) - Concomitant (341 days); Trade Name Not Specified (nivolumab) - Suspect (375 days); Xarelto (Rivaroxaban) - Concomitant (-)	Atrial fibrillation
480588	31/10/2019	Female	47	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (9 days)	Dyspnoea ; Throat irritation ; Throat tightness
480988	5/11/2019	Male	36	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Condition aggravated ; Contraindicated product administered
481269	7/11/2019	Male	17	██████████ (cannabidiol) - Suspect (0 days)	Aggression ; Anxiety

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
481270	7/11/2019	Male	-	██████████ (cannabidiol) - Suspect (-); Stelara (Ustekinumab) - Suspect (-); Trade Name Not Specified (Azathioprine) - Concomitant (-); Trade Name Not Specified (Pantoprazole) - Concomitant (-); Trade Name Not Specified (Prednisolone) - Concomitant (-); Trade Name Not Specified (Temazepam) - Suspect (-)	Increased appetite ; Nausea
481486	11/11/2019	Female	48	██████████ (cannabidiol) - Suspect (-)	Drug ineffective ; Limb injury
481626	12/11/2019	Female	91	██████████ (cannabidiol) - Suspect (-)	Product complaint ; Therapeutic response decreased
481693	13/11/2019	Male	68	██████████ (cannabidiol) - Suspect (-); Trade Name Not Specified (Product not Coded) - Concomitant (-)	Death
481728	13/11/2019	Male	68	██████████ (cannabidiol) - Suspect (-)	Death
481952	15/11/2019	Male	42	██████████ (cannabidiol) - Suspect (-)	Psychotic disorder
482277	20/11/2019	Female	24	██████████ (cannabidiol) - Suspect (-); Macrochantin (Nitrofurantoin) - Concomitant (-); Trade Name Not Specified (Baclofen) - Concomitant (-); Trade Name Not Specified (Diazepam) - Concomitant (-); Trade Name Not Specified (Omeprazole) - Concomitant (-); Trade Name Not Specified (Pregabalin) - Concomitant (-)	Ear haemorrhage ; Epistaxis
482531	22/11/2019	Male	70	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Depression ; Suicidal ideation
482535	22/11/2019	Female	51	██████████ (cannabidiol) - Suspect (-)	Hypertension
483512	5/12/2019	Male	35	Trade Name Not Specified (Paracetamol) - Suspect (-); Trade Name Not Specified (cannabidiol) - Suspect (-)	Abdominal discomfort ; Acute kidney injury ; Dehydration ; Overdose ; Renal impairment ; Vomiting ; Weight decreased
483672	7/12/2019	Female	66	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Depression ; Suicidal ideation
484124	13/12/2019	Male	48	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Psychotic behaviour
484504	18/12/2019	Female	47	Alphagan Eye Drops (brimonidine tartrate) - Concomitant (-); ██████████ cannabidiol) - Concomitant (-); Amoxil (amoxicillin trihydrate) - Concomitant (-16 days); Azarga 1%-0.5% Eye Drops (Brimonidine ; Timolol maleate) - Concomitant (-); Celebrex (Celecoxib) - Concomitant (-); Doxsig (doxycycline hyclate)	Hypersensitivity pneumonitis

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				(hydrochloride)) - Concomitant (-16 days); Endone (oxycodone hydrochloride) - Concomitant (-); Kapanol (morphine sulfate pentahydrate) - Concomitant (-); Lyrica (Pregabalin) - Concomitant (-); Movicol (macrogol 3350 ; potassium chloride ; sodium bicarbonate ; sodium chloride) - Concomitant (-); Nasonex Allergy (mometasone furoate) - Concomitant (-); Nexium (esomeprazole) - Concomitant (3 days); Nicotine Transdermal Patch (Nicotine) - Concomitant (-); Plaquenil (Hydroxychloroquine sulfate) - Concomitant (-); Prolia (Denosumab) - Concomitant (-); Propranolol (Propranolol hydrochloride) - Concomitant (-); Somac (Pantoprazole) - Concomitant (-); Symbicort Turbuhaler 200/6 (Budesonide ; formoterol (eformoterol) fumarate dihydrate) - Concomitant (-); Trade Name Not Specified (Aspirin) - Concomitant (-); Trade Name Not Specified (Bismuth subcitrate) - Concomitant (3 days); Trade Name Not Specified (Furazolidone) - Suspect (3 days); Trade Name Not Specified (Methotrexate) - Concomitant (-); Trade Name Not Specified (Ondansetron) - Concomitant (-); Trade Name Not Specified (Paracetamol) - Concomitant (-); Trade Name Not Specified (Perindopril) - Concomitant (-); Trade Name Not Specified (Prednisolone) - Concomitant (-); Trade Name Not Specified (ciclosporin) - Concomitant (-); Trade Name Not Specified (folic acid) - Concomitant (-); Vagifem Low (estradiol hemihydrate) - Concomitant (-); Xalatan (Latanoprost) - Concomitant (-)	
484641	19/12/2019	Female	68	Oestrogens Conjugated (conjugated estrogens) - Suspect (-); ██████████ (cannabidiol) - Concomitant (-); Trade Name Not Specified (progesterone) - Suspect (-)	Myocardial infarction
484977	27/12/2019	Male	67	██████████ (cannabidiol) - Suspect (-)	Confusional state
486400	21/01/2020	Female	27	Trade Name Not Specified (cannabidiol) - Concomitant (-); Tysabri (Natalizumab) - Suspect (-)	Multiple sclerosis relapse
486487	22/01/2020	Female	-	██████████ (cannabidiol) - Suspect (-)	Cardio-respiratory arrest ; Status epilepticus

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
486754	24/01/2020	Male	86	Trade Name Not Specified (CANNABIS SATIVA) - Concomitant (-); Trade Name Not Specified (Dexamethasone) - Concomitant (-); Xgeva (Denosumab) - Suspect (-)	Feeling abnormal ; Mental impairment ; Trigeminal nerve disorder
486914	29/01/2020	Male	-	Trade Name Not Specified (cannabidiol) - Suspect (-)	Malaise
486961	29/01/2020	Female	81	██████████ (cannabidiol) - Suspect (-); Aurorix (Moclobemide) - Concomitant (-); Eliquis (Apixaban) - Concomitant (-); Lasix M (furosemide (frusemide)) - Concomitant (-); Noten (Atenolol) - Concomitant (-); Ostelin Vitamin D (colecalfiferol) - Concomitant (-); Trade Name Not Specified (Candesartan cilexetil) - Concomitant (-); Trade Name Not Specified (Glucosamine hydrochloride) - Concomitant (-); Trade Name Not Specified (colecalfiferol) - Concomitant (-); Trade Name Not Specified (magnesium) - Concomitant (-); Trade Name Not Specified (zinc oxide) - Concomitant (-)	Cognitive disorder ; Dizziness ; Hyperhidrosis ; Nausea ; Syncope
487617	6/02/2020	Male	72	CEMIPLIMAB (CEMIPLIMAB) - Suspect (388 days); Chlorsig (Chloramphenicol) - Concomitant (29 days); Dextran (dextran 70 ; glucose monohydrate) - Concomitant (296 days); Paraffin (hard paraffin) - Concomitant (296 days); Trade Name Not Specified (Amitriptyline) - Concomitant (220 days); Trade Name Not Specified (Atenolol) - Concomitant (-); Trade Name Not Specified (Bisacodyl) - Concomitant (-); Trade Name Not Specified (CANNABIS SATIVA) - Concomitant (-); Trade Name Not Specified (Oxycodone) - Concomitant (-); Trade Name Not Specified (Paracetamol) - Concomitant (299 days); Trade Name Not Specified (Perindopril) - Concomitant (298 days); Trade Name Not Specified (Phenylephrine) - Concomitant (212 days); Trade Name Not Specified (Triamcinolone) - Concomitant (108 days); Trade Name Not Specified (Tropicamide) - Concomitant (237 days)	Arthralgia
487720	7/02/2020	Female	39	██████████ (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Deep vein thrombosis ; Ischaemic stroke ; Pulmonary embolism
488624	18/02/2020	Male	47	Invega Trinza (Paliperidone) - Suspect (-); Trade Name Not Specified (CANNABIS SATIVA) - Suspect (-); Trade Name Not Specified (ethanol) - Suspect (-)	Schizophrenia

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
488659	19/02/2020	Male	29	Clopine (clozapine) - Suspect (-); Clopine (clozapine) - Suspect (- 19 days); Clopine (clozapine) - Suspect (4052 days); Trade Name Not Specified (CANNABIS SATIVA) - Concomitant (-)	Atrial enlargement ; Defect conduction intraventricular ; Delusion ; Echocardiogram abnormal ; Electrocardiogram ST segment elevation ; Electrocardiogram T wave amplitude decreased ; Electrocardiogram T wave inversion ; Hostility ; Irritability ; Left ventricular hypertrophy ; Mitral valve incompetence ; Mitral valve thickening ; Pulmonary valve incompetence ; Sinus tachycardia ; Tachycardia ; Tricuspid valve incompetence
488921	21/02/2020	Female	68	[REDACTED] (cannabidiol) - Suspect (-)	Lip swelling ; Noninfective gingivitis ; Oral mucosal erythema ; Paraesthesia oral ; Pharyngeal swelling
489314	26/02/2020	Male	42	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (4 days)	Disorientation ; Euphoric mood ; Paraesthesia ; Vertigo
489324	26/02/2020	Female	49	[REDACTED] (cannabidiol) - Suspect (-)	Accidental overdose ; Disturbance in attention ; Feeling abnormal ; Muscle spasms ; Muscle twitching
489363	26/02/2020	Female	-	[REDACTED] (cannabidiol) - Suspect (-)	Hypersensitivity ; Nasal congestion
490245	7/03/2020	Male	47	[REDACTED] (cannabidiol) - Suspect (-)	Dizziness ; Headache ; Vomiting
490431	10/03/2020	Female	66	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (1 days)	Dysphoria ; Palpitations
490499	11/03/2020	Male	73	[REDACTED] (cannabidiol) - Suspect (-)	Dyspepsia ; Nausea
491318	23/03/2020	Male	74	[REDACTED] (cannabidiol) - Suspect (-); Circadin (Melatonin) - Concomitant (-); Endep (amitriptyline hydrochloride) - Concomitant (-); Endone (oxycodone hydrochloride) - Concomitant (-); Lyrica (Pregabalin) - Concomitant (-); Plavix (Clopidogrel) - Suspect (-); Somac (Pantoprazole) - Concomitant (-); Trade Name Not Specified (Aspirin) - Concomitant (-); Trade Name Not Specified (Product not Coded) - Concomitant (-); Trade Name Not Specified (atorvastatin) - Concomitant (-); Trade Name Not Specified	Hallucination

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
				(magnesium) - Concomitant (-); Tramadol SR (Tramadol hydrochloride) - Concomitant (-)	
491365	24/03/2020	Female	62	[REDACTED] (cannabidiol) - Suspect (-); [REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Cough ; Dysgeusia ; Nausea ; Vomiting ; Weight decreased
491375	24/03/2020	Female	-	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Chest discomfort ; Gastrointestinal disorder ; Nausea ; Throat irritation ; Throat irritation ; Throat tightness
492235	6/04/2020	Female	28	Enbrel (Etanercept) - Concomitant (-); Palexia SR (Tapentadol) - Concomitant (-); Panadeine Forte (codeine phosphate hemihydrate ; Paracetamol) - Concomitant (-); Seretide (fluticasone propionate ; Salmeterol xinafoate) - Concomitant (-); Solone (Prednisolone) - Concomitant (-); [REDACTED] (cannabidiol) - Suspect (-); Trade Name Not Specified (Pantoprazole) - Concomitant (-); Ventolin (Salbutamol) - Concomitant (-)	Exposure during pregnancy
493022	16/04/2020	Male	56	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-); [REDACTED] (Tetrahydrocannabinol (THC)) - Suspect (-)	Delusional disorder, unspecified type
493310	21/04/2020	Female	64	Lyrica (Pregabalin) - Concomitant (-); [REDACTED] (cannabidiol) - Suspect (-); Zoloft (Sertraline hydrochloride) - Concomitant (-)	Arthralgia ; Diarrhoea ; Rash
494047	29/04/2020	Male	46	Trade Name Not Specified (cannabidiol) - Suspect (-)	Asthma
494158	30/04/2020	Male	18	[REDACTED] (cannabidiol) - Suspect (-); Trade Name Not Specified (Clobazam) - Concomitant (-); Trade Name Not Specified (Levetiracetam) - Concomitant (-); Trade Name Not Specified (Topiramate) - Concomitant (-)	Seizure
494312	1/05/2020	Female	49	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-); [REDACTED] (cannabidiol) - Suspect (-)	Hypersensitivity
494316	1/05/2020	Female	9	[REDACTED] (cannabidiol) - Suspect (-)	Drug ineffective ; Liver function test increased

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
494528	4/05/2020	Female	64	Palexia (Tapentadol) - Concomitant (-); Panadol Osteo (Paracetamol) - Concomitant (-); [REDACTED] cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (204 days); Trade Name Not Specified (Irbesartan) - Concomitant (-); Trade Name Not Specified (Meloxicam) - Concomitant (-); Trade Name Not Specified (Omeprazole) - Concomitant (-); Trade Name Not Specified (Tapentadol) - Concomitant (-); Trade Name Not Specified (estradiol) - Concomitant (-); Trade Name Not Specified (furosemide (frusemide)) - Concomitant (-)	Squamous cell carcinoma ; Tongue disorder
495484	13/05/2020	Female	39	[REDACTED] (cannabidiol) - Suspect (-)	Anxiety
495647	14/05/2020	Male	22	[REDACTED] (cannabidiol) - Suspect (-)	Crying ; Palpitations
495850	18/05/2020	Female	59	Keflex (cefalexin monohydrate) - Concomitant (-); [REDACTED] (cannabidiol) - Suspect (-); Trade Name Not Specified (Mirtazapine) - Concomitant (-); Zolpidem (zolpidem tartrate) - Concomitant (-)	Renal pain
495853	18/05/2020	Female	70	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Anxiety ; Confusional state ; Euphoric mood ; Hyperventilation
496056	19/05/2020	Female	76	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Dizziness ; Feeling abnormal ; Somnolence
496139	19/05/2020	Female	80	[REDACTED] (cannabidiol) - Suspect (-)	Feeling abnormal
496141	19/05/2020	Female	75	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Abdominal pain
496379	20/05/2020	Female	12	Trade Name Not Specified (Cannabidivarin) - Suspect (-); Trade Name Not Specified (Risperidone) - Concomitant (-)	Drooling ; Hemiparesis
496387	20/05/2020	Female	13	Epilim (Sodium valproate) - Concomitant (-); Phenergan (Promethazine hydrochloride) - Concomitant (-); Trade Name Not Specified (Cannabidivarin) - Suspect (-)	Hemiparesis ; Somnolence
496399	20/05/2020	Male	50	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect (-)	Anxiety ; Depersonalisation/derealisation disorder ; Panic reaction
496604	21/05/2020	Male	44	[REDACTED] (CANNABIS SATIVA) - Suspect (-)	Feeling abnormal ; Headache ; Product complaint

The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. Adverse events are suspected of being related to a medicine, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors. There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case No.	Report Entry Date	Gender	Age	Medicines reported as being taken	MedDRA reaction terms
496835	25/05/2020	Male	50	[REDACTED] (cannabidiol) - Suspect (0 days)	Psychotic symptom